The Human Variable 

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating, multi-system neuroimmune disease on par with multiple sclerosis or congestive heart failure in severity, but for decades, it’s been sidelined by global health systems. Underdiagnosis, outdated clinical criteria, systemic bias, and institutional inertia have obscured its true scale. The result: tens of millions worldwide excluded from diagnosis, care, or recognition.

They called your symptoms anecdotal. They called your story rare. But inside your medical records, flare journals, and sleepless nights is the dataset no one bothered to decode. This isn’t just a blog post, it’s a call to reclaim your role as more than a subject. Inside, we share how a self-paced case study course helps patients and caregivers turn lived experience into lasting change.

Introduction Myalgic encephalomyelitis/chronic fatigue syndrome is common, costly, and routinely missed until someone reads the chart as a timeline. Patients describe a delayed crash after effort that lasts days to weeks. CDC and NICE name this pattern post-exertional malaise and make it central to diagnosis (CDC, 2024; NICE NG206, 2021). Yet most people with ME/CFS still do not have a diagnosis, and many wait years for recognition, with the National Academies reporting both

Innovative Orthostatic Intolerance & POTS Detection for Faster Diagnosis. Orthostatic intolerance and POTS are increasingly more common, disabling, and often missed until someone reads the chart as a timeline. The signs of these conditions already lives in routine positions and vitals clinicians collect anyway: triage after upright waiting, first supine on the bed, a short bathroom walk and return, and discharge.

The CDF-ME framework captures between 88–94% of patients who meet International Consensus Criteria (ICC), Canadian Consensus Criteria (CCC), or the National Academies of Sciences, Engineering, and Medicine (NASEM) diagnostic criteria, regardless of whether their illness was triggered by infection, vaccination, physical trauma, or environmental exposure. Validated through CYNAERA’s AI engine and over 200,000 patient simulations, CDF-ME integrates high-specificity markers .

STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”